Inducible nitric oxide synthase (iNOS/NOS2) is a high-output enzyme upregulated during inflammatory activation, primarily in M1 macrophages, that catalyzes massive nitric oxide (NO) production from L-arginine for pathogen killing and immune signaling. Unlike constitutive NOS isoforms (eNOS, nNOS) that produce nanomolar NO for vascular or neural signaling, iNOS generates micromolar concentrations — a 100-1000x difference that shifts NO from messenger to weapon. Expression is transcriptionally controlled by NF-κB, IRF1, and STAT1 in response to inflammatory triggers (IFN-γ, LPS, TNF-α), and the enzyme competes directly with arginase-1 for L-arginine substrate, making the iNOS/arginase balance a key determinant of macrophage polarization and tissue fate.
Think of iNOS as a munitions factory that only opens during wartime. Your body's macrophages are like border towns — in peacetime (M2), they run repair workshops using arginine to build collagen and heal wounds via arginase-1. But when enemy signals arrive (bacteria releasing LPS, T cells shouting IFN-γ), the town council (NF-κB transcription factor) votes to convert the workshop into a bomb factory. The same raw material (L-arginine trucks arriving at the loading dock) now gets diverted to iNOS assembly lines instead of arginase repair benches. iNOS churns out nitric oxide grenades at factory scale — not the gentle puffs that relax blood vessels (eNOS), but massive plumes (μM concentrations) that react with superoxide to form peroxynitrite, a chemical weapon that punches holes in bacterial walls and kills invaders. The problem: you can't run a bomb factory and a repair workshop simultaneously in the same building. The arginine supply is finite. If the war drags on and iNOS stays open too long, the tissue never heals — chronic inflammation locks the macrophages in M1 mode, and the constant oxidative bombardment damages your own infrastructure. IL-4 and IL-13 are like peace treaties that shut down the munitions plant and reopen the repair shop.
Transcriptional Induction:
- Inflammatory triggers (LPS binding TLR4, IFN-γ binding IFNGR, TNF-α binding TNFR) activate intracellular cascades
- TLR4/MyD88 pathway → IκB kinase → phosphorylates IκB → releases NF-κB → nuclear translocation
- IFN-γ/JAK pathway → phosphorylates STAT1 → STAT1 homodimers translocate to nucleus
- NF-κB + STAT1 + IRF1 bind to iNOS gene promoter (chromosome 17 in humans)
- Transcription of iNOS mRNA → translation yields ~130 kDa homodimer protein
Enzymatic Catalysis:
graph TD
A["L-arginine + O2"] -->|iNOS enzyme| B["NO• + L-citrulline"]
B --> C[NO• reacts with O2•-]
C --> D[ONOO- peroxynitrite]
D --> E1[Bacterial membrane damage]
D --> E2[DNA fragmentation]
D --> E3[Mitochondrial dysfunction]
F[Cofactors required] --> G1[NADPH]
F --> G2[FAD]
F --> G3[FMN]
F --> G4[Tetrahydrobiopterin BH4]
F --> G5[Heme]
H[Arginine competition] --> I{Available L-arginine}
I -->|M1 state| J[iNOS dominates]
I -->|M2 state| K[Arginase-1 dominates]
L[IL-4/IL-13 signaling] --> M[STAT6 activation]
M --> N[Suppress iNOS transcription]
M --> O[Induce arginase-1]
Molecular Details:
- L-arginine + 1.5 NADPH + 2 O2 → NO + L-citrulline + 1.5 NADP+ + 2 H2O
- Each iNOS monomer contains binding sites for: arginine, BH4 (tetrahydrobiopterin), heme, FAD, FMN, NADPH
- Produces sustained NO output (hours to days) vs. eNOS (seconds to minutes)
- NO concentration range: 0.5-5 μM (vs. eNOS: 1-100 nM)
- Km for arginine ~10 μM; saturated under most physiological conditions
- NO diffusion radius ~200 μm, half-life in tissue ~1 second
Peroxynitrite Formation:
NO• + O2•- → ONOO- (near diffusion-limited reaction, k = 10^10 M-1s-1)
- Peroxynitrite nitrates tyrosine residues → 3-nitrotyrosine (protein dysfunction marker)
- Oxidizes lipids → membrane damage
- Causes DNA strand breaks → activates PARP → NAD+ depletion → cell death
Substrate Competition:
Both iNOS and arginase-1 require L-arginine:
- M1 phenotype: high iNOS, low arginase-1 → arginine → NO → pathogen killing
- M2 phenotype: low iNOS, high arginase-1 → arginine → ornithine → proline/polyamines → collagen synthesis and cell proliferation
- Arginine depletion ("arginine steal") can suppress T cell proliferation (requires arginine for TCR signaling)
M1/M2 Polarization Marker:
iNOS is the single most reliable biochemical signature of M1 inflammatory macrophages. Measuring iNOS expression (via mRNA, protein, or NO metabolites like nitrite/nitrate) reveals whether tissue macrophages are in kill mode or repair mode. This is critical for understanding why wounds don't heal, why chronic inflammatory diseases persist, and why resolution therapies (omega-3 SPMs, IL-4/IL-13 inducers) work — they flip the iNOS/arginase switch.
Chronic Inflammation and Tissue Damage:
In conditions like rheumatoid arthritis, inflammatory bowel disease, atherosclerosis, and neurodegenerative diseases, sustained iNOS activation creates a vicious cycle:
- Ongoing antigen presentation → IFN-γ from Th1 cells → persistent iNOS expression
- Chronic high NO → peroxynitrite → oxidative damage to host tissue
- Damaged tissue releases more DAMPs → perpetuates M1 activation
- Arginine depletion → collateral suppression of T cell responses and repair pathways
Evolutionary and Metabolic Context:
iNOS represents an evolutionary trade-off: essential for clearing intracellular pathogens (tuberculosis, Leishmania, Salmonella) but toxic if left on too long. Hunter-gatherer immune systems likely toggled M1/M2 rapidly in response to acute infections. Modern mismatch (chronic low-grade endotoxemia from gut dysbiosis, obesity-induced metaflammation, psychosocial stress activating NF-κB) keeps iNOS chronically elevated — the munitions factory never shuts down. This aligns with the selfish immune system concept: immune cells prioritize their own survival and function (pathogen killing) even at the expense of whole-organism health (tissue repair, metabolic efficiency).
Intervention Points:
- Downregulate iNOS transcription: Resolvins (RvD1, RvE1), IL-10, vagus nerve stimulation (cholinergic anti-inflammatory pathway), curcumin, resveratrol (NF-κB inhibitors)
- Shift to M2 phenotype: IL-4/IL-13 inducers (omega-3 SPMs, helminth therapy, type 2 cytokine pathways), exercise-induced myokines (IL-6 pulse → IL-10), cold exposure (→ catecholamines → β2-adrenergic M2 shift)
- Support arginine availability: L-arginine supplementation (3-6 g/day), reduce arginase-1 competition in M2-dominant scenarios, citrulline supplementation (bypasses arginase to regenerate arginine)
- Reduce oxidative stress: Antioxidants (glutathione, vitamin E, polyphenols) to limit peroxynitrite damage
Clinical Thresholds:
- Plasma/serum nitrite + nitrate (NOx) as iNOS activity proxy: elevated >40 μM suggests systemic iNOS activation
- Tissue 3-nitrotyrosine immunostaining: marker of peroxynitrite formation
- Macrophage iNOS mRNA >10-fold baseline (qPCR) indicates M1 polarization
- Exhaled NO: >25 ppb in asthma reflects airway iNOS activity
Exam-Relevant Concept:
iNOS is the molecular battleground where inflammation vs. resolution is decided. A patient with non-healing wounds, chronic fatigue, or autoimmune disease likely has macrophages stuck in iNOS-dominant M1 mode. Clinical PNI interventions aim to restore metabolic flexibility at the macrophage level — enabling the iNOS→arginase switch that allows resolution and repair.
- Produces NO at 0.5-5 μM (100-1000x higher than eNOS nanomolar output)
- Induced within 4-6 hours of LPS/IFN-γ exposure; sustained for days if stimulus persists
- Primary inducers: IFN-γ (from Th1/NK cells), LPS (via TLR4), TNF-α, IL-1β
- Transcriptional control: NF-κB, STAT1, IRF1 bind iNOS promoter
- Requires 5 cofactors: NADPH, FAD, FMN, tetrahydrobiopterin (BH4), heme
- Competes with arginase-1 for L-arginine (Km ~10 μM for both enzymes)
- NO + superoxide → peroxynitrite (ONOO-), reaction rate 10^10 M-1s-1
- Peroxynitrite creates 3-nitrotyrosine adducts (oxidative damage biomarker)
- Essential for killing Mycobacterium tuberculosis, Leishmania, Toxoplasma (intracellular pathogens)
- Excessive iNOS in sepsis causes hypotension (vasodilation), tissue hypoxia, multi-organ failure
- IL-4 and IL-13 suppress iNOS via STAT6 → arginase-1 induction (M1→M2 switch)
- Chronic iNOS activation depletes arginine → impairs T cell proliferation (arginine-dependent TCR signaling)
- iNOS knockout mice are highly susceptible to bacterial infections but protected from septic shock
- Human iNOS gene on chromosome 17q11.2; polymorphisms affect autoimmune disease risk
- Clinical iNOS inhibitors (aminoguanidine, L-NIL) show efficacy in animal models but failed in human sepsis trials (too broad suppression of immune function)
- M1 macrophages — is signature enzyme and biochemical marker of
- M2 macrophages — is transcriptionally suppressed in via IL-4/IL-13 signaling
- nitric oxide — produces in micromolar concentrations for cytotoxicity
- L-arginine — requires as substrate, competing with arginase-1
- arginase 1 — competes directly for arginine substrate; M1/M2 switch determined by iNOS/arginase ratio
- NF-κB — is transcriptionally induced by; primary transcription factor binding promoter
- IFN-gamma — is induced by; strongest transcriptional trigger from Th1/NK cells
- LPS — is induced by via TLR4/MyD88 pathway activation
- TNF-α — is induced by; amplifies NF-κB signaling
- peroxynitrite — produces via NO + superoxide reaction; major cytotoxic effector
- oxidative stress — generates massive oxidative/nitrosative stress via peroxynitrite
- macrophage polarization — determines phenotype; iNOS expression defines M1 state
- wound healing — impairs when chronically active; prevents M1→M2 transition
- inflammation — is central enzyme of inflammatory macrophage activation
- IL-4 — is suppressed by via STAT6 pathway
- IL-13 — is suppressed by via STAT6 pathway
- IL-10 — is suppressed by; resolution cytokine downregulates iNOS transcription
- sepsis — excessive activation causes hypotension, organ failure in septic shock
- tuberculosis — is required for immune defense; iNOS-deficient mice cannot clear infection
- NADPH — requires as electron donor for catalytic cycle
- tetrahydrobiopterin — requires as essential cofactor; BH4 deficiency uncouples iNOS → superoxide production
- Resolvins — downregulate iNOS expression; RvD1/RvE1 suppress NF-κB signaling
- SPMs — specialized pro-resolving mediators suppress iNOS transcription and shift to arginase-1
- TLR4 — is activated by LPS binding, triggering iNOS expression
- JAK-STAT — pathway mediates IFN-γ induction via STAT1 phosphorylation
- STAT1 — transcription factor essential for IFN-γ-induced iNOS expression
- IRF1 — interferon regulatory factor cooperates with NF-κB for iNOS transcription
- chronic inflammation — sustained iNOS activity is hallmark of chronic inflammatory states
- atherosclerosis — iNOS in plaque macrophages contributes to oxidative LDL modification
- rheumatoid arthritis — synovial iNOS produces NO causing cartilage degradation
- inflammatory bowel disease — intestinal macrophage iNOS drives mucosal damage
- neurodegenerative diseases — microglial iNOS activation contributes to neuronal damage in Alzheimer's, Parkinson's
- Th1 cells — produce IFN-γ that induces macrophage iNOS expression
- NK cells — early IFN-γ source for iNOS induction during innate response
- endotoxemia — chronic gut-derived LPS elevates systemic iNOS activity
- metaflammation — obesity-induced low-grade inflammation includes adipose tissue macrophage iNOS
- vagus nerve — cholinergic anti-inflammatory pathway suppresses iNOS via α7nAChR signaling
- curcumin — inhibits NF-κB nuclear translocation, reducing iNOS transcription
- resveratrol — polyphenol that suppresses iNOS expression via SIRT1/NF-κB modulation
- omega-3 fatty acids — EPA/DHA reduce iNOS expression and promote M2 shift
- exercise — acute exercise induces transient IL-6 pulse → IL-10 → iNOS suppression
- cold exposure — catecholamine release → β2-adrenergic signaling → M2 polarization, iNOS downregulation
- Module 3 — Immune system fundamentals, macrophage polarization
- Module 5 — Inflammation and resolution, metabolic-immune integration